Results 21 to 30 of about 4,629,468 (340)

Selective IL-13 inhibitors for the treatment of atopic dermatitis

Drugs in Context, 2021
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic factors.
Francisca Gonçalves, Egídio Freitas, Tiago Torres   +2 more
doaj   +1 more source

Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis

Frontiers in Immunology, 2023
BackgroundFibrostenotic disease is a common complication in Crohn’s disease (CD) patients hallmarked by transmural extracellular matrix (ECM) accumulation in the intestinal wall.
Kristina Koop, Karin Enderle, Miriam Hillmann, Laura Ruspeckhofer, Michael Vieth, Gregor Sturm, Zlatko Trajanoski, Zlatko Trajanoski, Anja A. Kühl, Anja A. Kühl, Raja Atreya, Raja Atreya, Moritz Leppkes, Patrick Baum, Janine Roy, Andrea Martin, Markus F. Neurath, Markus F. Neurath, Clemens Neufert, Clemens Neufert   +19 more
doaj   +1 more source

Association of interleukin-13 gene variants with susceptibility to brucellosis [PDF]

Trends in Pharmaceutical Sciences, 2016
Brucella is an intracellular Gram-negative bacterium. Previous reports showed that gene polymorphisms of cytokines can affect resistance or susceptibility to Brucella infection.
Sayed-Jalal-Aladin Ashraf-Mansuri, Manoochehr Rasouli, Sohrab Najafipour, Ali Moravej, Mehdi Kalani, Manica Negahdaripour   +5 more
doaj   +2 more sources

Interleukin-13 drives metabolic conditioning of muscle to endurance exercise

Science, 2020
IL-13 hits the gym Interleukin-13 (IL-13) is a cytokine secreted by T cells, innate lymphoid cells (ILC2s), and granulocytes. It acts as a central mediator in allergy and antihelminth defense with various effects. Knudsen et al.
Nelson H. Knudsen, Kristopher J. Stanya, Alexander L. Hyde, Mayer M. Chalom, Ryan K. Alexander, Yae-Huei Liou, Kyle A. Starost, Matthew R. Gangl, David Jacobi, Sihao Liu, Danesh H Sopariwala, Diogo Fonseca-Pereira, Jun Li, F. Hu, W. Garrett, V. Narkar, E. Ortlund, Jonathan H. Kim, C. Paton, J. Cooper, Chih‐Hao Lee   +20 more
semanticscholar   +1 more source

Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. [PDF]

, 2015
Chronic pancreatitis (CP) is a progressive and irreversible inflammatory and fibrotic disease with no cure. Unlike acute pancreatitis (AP), we find that alternatively activated macrophages (AAMs) are dominant in mouse and human CP.
Chawla, Ajay, Habtezion, Aida, Hsieh, Michael H, Murali, Ramachandran, Pandol, Stephen J, Sharma, Vishal, Xue, Jing   +6 more
core   +2 more sources

Mutants of Interleukin 13 with Altered Reactivity toward Interleukin 13 Receptors [PDF]

Journal of Biological Chemistry, 1999
Interleukin 13 (IL13) belongs to a family of cytokines whose members exhibit structural homology, despite amino acid sequence dissimilarity. For example, while of limited sequence homology, IL13 and IL4 share a signaling receptor, IL13/4 receptor, on a variety of human normal cells. However, a subclass of IL4-independent IL13 receptors is overexpressed
J P, Thompson, W, Debinski
openaire   +2 more sources

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

Allergy. European Journal of Allergy and Clinical Immunology, 2020
Atopic dermatitis (AD) is a common inflammatory skin condition that has traditionally been considered a paradigmatic type 2 immunity (T2)‐driven disease.
T. Bieber
semanticscholar   +1 more source

The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling [PDF]

, 2008
The kinases MSK1 and MSK2 are activated 'downstream' of the p38 and Erk1/2 mitogen-activated protein kinases. Here we found that MSK1 and MSK2 were needed to limit the production of proinflammatory cytokines in response to stimulation of primary ...
A Cuenda, A Soloaga, A Sommer, Andrew Wingate, B Echtenacher, B Echtenacher, BG Stiles, C Platzer, CA Gogos, Claire E Monk, Claus Johansen, D Rittirsch, DM Dambach, ER Ottosen, F Hildebrand, FY Liew, GR Wiggin, GY Song, H Chi, J Bain, J Darragh, J Han, J Rouse, J Simon C Arthur, Jin Mo Park, JM Park, Joanne Darragh, Joanne McIlrath, JS Arthur, JS Arthur, Julia M Carr, KV Salojin, Lars Iversen, M Brook, M Hammer, M Saraiva, ML Steinhauser, MS Lee, NC Riedamann, NW Freshney, Olga Ananieva, OM Peck-Palmer, P Chen, PC Cheung, PJ Murray, Q Zhao, R Kuhn, Rachel Toth, SE Moreno, SJ O'Keefe, SM Miggin, SQ Latifi, Susana G Santos, T Kawai, T Lang, T van der Poll, VA Beardmore, VS Carl, WJ Hubbard, X Zhang, Y Kalechman, YJ Kang   +61 more
core   +3 more sources

Characterization of the Interaction between Interleukin-13 and Interleukin-13 Receptors [PDF]

Journal of Biological Chemistry, 2005
Interleukin-13 (IL-13) possesses two types of receptor: the heterodimer, composed of the IL-13Ralpha1 chain (IL-13Ralpha1) and the IL-4Ralpha chain (IL-4Ralpha), transducing the IL-13 signals; and the IL-13Ralpha2 chain (IL-13Ralpha2), acting as a nonsignaling "decoy" receptor.
Kazuhiko, Arima, Kazuo, Sato, Go, Tanaka, Sachiko, Kanaji, Tohru, Terada, Eijiro, Honjo, Ryota, Kuroki, Yo, Matsuo, Kenji, Izuhara   +8 more
openaire   +2 more sources

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

JAMA dermatology, 2020
This phase 2b, placebo-controlled, randomized clinical trial evaluates the efficacy and safety of lebrikizumab, a novel, high-affinity, monoclonal antibody targeting interleukin (IL)–13 that selectively prevents formation of the IL-13Rα1/IL-4Rα ...
E. Guttman‐Yassky, A. Blauvelt, L. Eichenfield, A. Paller, A. Armstrong, J. Drew, R. Gopalan, E. Simpson   +7 more
semanticscholar   +1 more source